Home

senza-titolo
To unify efforts and expertise to reduce cancer related suffering and mortality through decreasing the incidence of advanced disease

 

Mediterranean Task force for Cancer Control

Cancer Prevention, Screening and Early Detection are rather neglected actions in most of the Mediterranean bordering countries, with sensitive burden on health costs and suffering incurred for the cure of advanced stage disease. Due to the aging of population and the changes in environment and lifestyles, cancer incidence and mortality are becoming a global health emergency. They will soon become a priority for national Health Authorities, also in view of decreasing economic resources. World Health Organization’s data clearly show how survival of cancer patients, because of late diagnosis, is directly proportional to the amounts of resources allocated to prevention and early diagnosis.

A Mediterranean Task Force for Cancer Control (MTCC) was established in 2004 as a Non Profit non Governamental  Organization (NGO), open to representatives of the Mediterranean bordering countries as well as other countries.

Representatives from Albania, Algeria, Bosnia-Herzegovina, Bulgaria, Croatia, Egypt, France, Greece, Iran, Italy, Jordan, Kosovo, Lebanon, Libya, Macedonia, Montenegro, Morocco, Palestine, Portugal, Slovenia, Spain, Syria, Tunisia, Turkey. IARC and UICC expressed their support to the initiative.

The MTCC, managed by responsible and reputed professionals, aims to influence at the national level the appropriate institutions and bodies (lawmakers, stakeholders, health officials, voluntary organizations, etc.) to prioritize health policies which enforce  prevention and early diagnosis, in contrasting the foreseen increasing cancer burden.

A call for action

Among Non-Communicable Diseases, Cancer has been recognized, by the United Nations in 2013, a Global Emergency. http://www.who.int/nmh/events/un_ncd_summit2011/en/

In this context, Prevention and Early Diagnosis are recommended as priority strategies in view of the diminishing economic resources and the skyrocketing prices of treating advanced disease. The latters will undoubtedly produce a broader unequal access to treatments resulting from differences in individual income.

Although cancer research has progressed at rapid pace, a gap remains between what is known about how to improve cancer prevention and early diagnosis and what is implemented as best practices in given health system and communities (Cancer Epidemiol Biomark. Prev. 23(11); 2512–21. 2014 ).

This is medically Unjustified and Unethical under whatsoever point of view and for any health provider , since the large proportion of the most commonly occurring tumors can be efficiently prevented and diagnosed at early curable stages.

Thus dissemination and implementation policies, which seek to pursue means of translating effective interventions into practice, is critical to narrowing the present research-to-practice gap, otherwise bound to wide

MTCC has recognized these issues, since 2005, as funding mission and legacy (see AIMS and Mission) by enboding in the By-Laws (see art.2) these principles (see By-Laws Section):

  • reduce cancer mortality and the burden of advanced disease in the Mediterranean area by promoting prevention/early diagnosis;
  • promote collection and use of information for professional and public education;
  • increase the proportion of Mediterranean citizens who have access to state-of-art cancer screenings, diagnoses, treatments and palliative care;
  • influence policies and promote programs and activities to eliminate disparities in cancer control in relation to gender, race ethnicity, insurance & socio-economic status, and place of residence.

Thus MTCC acted consequently addressing this alarming situation by three specific actions:

Information: Multilingual Primary and Secondary Prevention Brochures;

Education : Postgraduate Courses;

Training: Full immersion Teaching Courses.

MTCC advocates that Cancer is not only a medical  issue but requires the involvement of the largest number of stakeholders, including non-doctor health officers, administrators, schools, patients’ advocacy groups , survivors ( see Past Activities).